Iterum Therapeutics PLC
NASDAQ:ITRM
Iterum Therapeutics PLC
Research & Development
Iterum Therapeutics PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Research & Development
-$4.2m
|
CAGR 3-Years
36%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Research & Development
-$101.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
6%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Research & Development
-$809.3m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-20%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Research & Development
-$39.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-4%
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Research & Development
-€47.1m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-7%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Research & Development
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Iterum Therapeutics PLC
Glance View
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 13 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The firm also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.
See Also
What is Iterum Therapeutics PLC's Research & Development?
Research & Development
-4.2m
USD
Based on the financial report for Sep 30, 2025, Iterum Therapeutics PLC's Research & Development amounts to -4.2m USD.
What is Iterum Therapeutics PLC's Research & Development growth rate?
Research & Development CAGR 5Y
36%
Over the last year, the Research & Development growth was 78%. The average annual Research & Development growth rates for Iterum Therapeutics PLC have been 36% over the past three years , 36% over the past five years .
